Switch theme
Sign up to access all valuation multiples
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.
2013
43
LTM Revenue $3.6M
LTM EBITDA -$22.8M
$1.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SanBio has a last 12-month revenue (LTM) of $3.6M and a last 12-month EBITDA of -$22.8M.
In the most recent fiscal year, SanBio achieved revenue of n/a and an EBITDA of -$20.5M.
SanBio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SanBio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $3.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$22.8M | XXX | -$20.5M | XXX | XXX | XXX |
| EBITDA Margin | -639% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$23.0M | XXX | -$24.1M | XXX | XXX | XXX |
| EBIT Margin | -643% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$19.0M | XXX | -$19.8M | XXX | XXX | XXX |
| Net Margin | -532% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, SanBio's stock price is JPY 3015 (or $21).
SanBio has current market cap of JPY 217B (or $1.5B), and EV of JPY 215B (or $1.5B).
See SanBio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.5B | $1.5B | XXX | XXX | XXX | XXX | $-0.27 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, SanBio has market cap of $1.5B and EV of $1.5B.
SanBio's trades at n/a EV/Revenue multiple, and -72.7x EV/EBITDA.
Equity research analysts estimate SanBio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SanBio has a P/E ratio of -78.3x.
See valuation multiples for SanBio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV/Revenue | 411.8x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -64.5x | XXX | -72.7x | XXX | XXX | XXX |
| EV/EBIT | -64.1x | XXX | -59.6x | XXX | XXX | XXX |
| EV/Gross Profit | 411.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -78.3x | XXX | -75.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -57.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSanBio's last 12 month revenue growth is 183%
SanBio's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.6M for the same period.
SanBio's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
SanBio's rule of X is -181% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for SanBio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 183% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -639% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -3% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -181% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SanBio acquired XXX companies to date.
Last acquisition by SanBio was XXXXXXXX, XXXXX XXXXX XXXXXX . SanBio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was SanBio founded? | SanBio was founded in 2013. |
| Where is SanBio headquartered? | SanBio is headquartered in Japan. |
| How many employees does SanBio have? | As of today, SanBio has 43 employees. |
| Who is the CEO of SanBio? | SanBio's CEO is Mr. Toru Kawanishi. |
| Is SanBio publicy listed? | Yes, SanBio is a public company listed on TKS. |
| What is the stock symbol of SanBio? | SanBio trades under 4592 ticker. |
| When did SanBio go public? | SanBio went public in 2015. |
| Who are competitors of SanBio? | Similar companies to SanBio include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of SanBio? | SanBio's current market cap is $1.5B |
| What is the current revenue of SanBio? | SanBio's last 12 months revenue is $3.6M. |
| What is the current revenue growth of SanBio? | SanBio revenue growth (NTM/LTM) is 183%. |
| What is the current EV/Revenue multiple of SanBio? | Current revenue multiple of SanBio is 411.8x. |
| Is SanBio profitable? | Yes, SanBio is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of SanBio? | SanBio's last 12 months EBITDA is -$22.8M. |
| What is SanBio's EBITDA margin? | SanBio's last 12 months EBITDA margin is -639%. |
| What is the current EV/EBITDA multiple of SanBio? | Current EBITDA multiple of SanBio is -64.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
